Eliquis is a factor xa inhibitor indicated:
To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
For the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe), in patients who have undergone hip or knee replacement surgery.
For the treatment of dvt and pe, and for the reduction in the risk of recurrent dvt and pe following initial therapy.
Disclaimer: CTX Lifesciences respects patent laws and conventions of pharmaceuticals as applicable in different countries.
API/Substances covered by patent are not offered to the countries where the patent law is in force. However, the final responsibility lies with the customer.